Notas de prensa

  • 13 de mayo de 2008
  • 161

Amgen VP of Investor Relations Arvind Sood to Present at the Baird Growth Stock Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--May 13, 2008--Amgen (NASDAQ:AMGN) Vice President of Investor Relations Arvind Sood will present at the RW Baird Growth Stock Conference on Wednesday, May 14, 2008 beginning at 8:55 a.m. Central Time. Live audio of the presentation will be available over the Internet and can be accessed from Amgen´s Web site, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are noted on Amgen´s Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science´s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people´s lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks David Polk, 805-447-4613 (media) Cory Rivera, 805-447-1060 (investors) SOURCE: Amgen

Destacadas

  • XIV Curso de Cáncer Hereditario de SEOM

    Farmanews Farmanews

    XIV Curso de Cáncer Hereditario de SEOM

    Leer más
  • Giromed Institute y Pangaea Oncology crean Pectus Respiratory Health e inaugurarán un centro de investigación de enfermedades respiratorias en Girona

    Patricia Morén

    Giromed Institute y Pangaea Oncology crean Pectus Respiratory Health e inaugurarán un centro de investigación de enfermedades respiratorias en Girona

    Leer más
  • Las presentaciones atípicas pueden retrasar el diagnóstico de la XLH en hasta un 50% de los pacientes

    Alba Martín

    Las presentaciones atípicas pueden retrasar el diagnóstico de la XLH en hasta un 50% de los pacientes

    Leer más

Newsletter

Suscríbete para conocer las novedades del mundo farmacéutico y sanitario.

¿Qué es?

FarmaNews pone a disposición de los medios y departamentos de comunicación, un canal para publicar notas de prensa y convocatorias del mundo sanitario y farmacéutico.

Contacto

Avda. Mare de Déu de Lourdes, 108,
08757, Corbera de Llobregat
(Barcelona), España